Evaluating c-Kit Mutation as a Marker in Acute Myeloid Leukemia

Absolute Quantification of c-Kit Mutation as MRD in Acute Myeloid Leukemia: a Prospective Observational Study

This study is testing if c-Kit mutations can help doctors better track and predict the risk of relapse in patients with acute myeloid leukemia by comparing it to other monitoring methods.

Quick facts

• Study type: Observational
• Enrollment: 50 (estimated)
• Ages: 14 Years and up
• Sex: All
• Sponsor: Institute of Hematology & Blood Diseases Hospital, China (Academic / other)
• Locations: 1 site (Tianjin)
• Trial ID: NCT06116318 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the clinical significance of c-Kit mutations as a molecular marker for minimal residual disease (MRD) in patients with acute myeloid leukemia (AML). It will compare the prognostic value of c-Kit mutations against other established MRD monitoring techniques. The study seeks to determine if combining multiple MRD markers, including c-Kit mutations, can provide a more accurate risk assessment for recurrence in AML patients. By analyzing the relationship between different MRD results, the study hopes to enhance the understanding of c-Kit mutations in disease monitoring.

Who should consider this trial

Good fit: Ideal candidates for this study are patients diagnosed with acute myeloid leukemia who have the c-Kit D816 mutation.

Not a fit: Patients with other mutations or those not meeting the diagnostic criteria for AML may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could improve the accuracy of MRD monitoring in AML, leading to better patient management and outcomes.

How similar studies have performed: While the specific approach of using c-Kit mutations as MRD monitoring is novel, existing studies have shown the importance of multiple MRD markers in assessing recurrence risk.

Eligibility criteria

Inclusion Criteria:

Patients who meet the diagnostic criteria(WHO 2016 criteria) of AML and have c-Kit D816 mutation. And receive treatment.

Exclusion Criteria:

Patients with other factors which were considered unsuitable to participate in the study by the investigators

Where this trial is running

Tianjin

• Institute of Hematology & Blood Diseases Hospital — Tianjin, China (Recruiting)

Study contacts

• Study coordinator: Hui Wei, Doctor

Conditions C-KIT Mutation; Acute myeloid leukemia; c-Kit mutation; MRD